default author photo

Andrea Botticelli

Sapienza University of Rome

SCHOLARLY PAPERS

3

DOWNLOADS

228

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Efficacy and Safety of Systemic Therapies Following Progression on CDK4/6 Inhibitors in Patients with HR+/HER2-- Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis

Number of pages: 35 Posted: 13 Jun 2025
Scuola Superiore Meridionale, Vanvitelli University of Campania Luigi Vanvitelli, University of Naples Federico II, Baylor College of Medicine, University of Milan, University of Padova, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), Sapienza University of Rome, Baylor College of Medicine, Harvard University - Dana-Farber Cancer Institute, University of Naples Federico II, University of Naples Federico II, University of Naples Federico II, Fondazione IRCCS Istituto Nazionale dei Tumori, Gustave Roussy, Fondazione IRCCS Istituto Nazionale dei Tumori, Azienda USL Toscana Centro - Sandro Pitigliani Translational Research Unit, University of Udine - Deparment of Medicine (DAME), University of Naples Federico II, Vanvitelli University of Campania Luigi Vanvitelli, IRCCS-Fondazione Bietti and Baylor College of Medicine
Downloads 146 (505,974)

Abstract:

Loading...

HR+/HER2- metastatic breast cancer, CDK4/6 inhibitor resistance, Systematic Review, Network meta-analysis, Biomarker-driven therapy, Antibody-drug conjugates

2.

Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2

Number of pages: 34 Posted: 12 Sep 2025
Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Università di Padova - Dipartimento di Scienze Chirurgiche, European Institute of Oncology (IEO) IRCCS - Division of New Drugs and Early Drug Development for Innovative Therapies, Baylor College of Medicine, Sapienza University of Rome, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), Fondazione IRCCS Policlinico San Matteo, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, ASST Papa Giovanni XXIII, affiliation not provided to SSRN, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Azienda Socio Sanitaria Territoriale Lariana, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori and Fondazione IRCCS Istituto Nazionale dei Tumori
Downloads 52 (1,041,696)

Abstract:

Loading...

HR+/HER2- advanced breast cancer, CDK4/6 inhibitors, Real-world, progression-free survival, Lobular histology, PALMARES-2

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Number of pages: 17 Posted: 12 Jan 2026
affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, London School of Hygiene & Tropical Medicine - Cancer Survival Group, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Sapienza University of Rome, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Padua - Department of Medicine, Università di Padova - Dipartimento di Scienze Chirurgiche and affiliation not provided to SSRN
Downloads 19 (1,513,226)

Abstract:

Loading...

Breast Cancer, HER2-low, machine-learning

Development of a machine learning model to guide further metastatic biopsy decision in patients with HER2-0 status on both primary breast cancer and first biopsied metastatic site: who should undergo a repeated biopsy to detect HER2-low gain?

Number of pages: 17 Posted: 14 Jan 2026
affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, London School of Hygiene & Tropical Medicine - Cancer Survival Group, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Sapienza University of Rome, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Padua - Department of Medicine, Università di Padova - Dipartimento di Scienze Chirurgiche and affiliation not provided to SSRN
Downloads 11 (1,598,105)

Abstract:

Loading...

breast cancer, HER2-low, machine-learning